Research programme: cardiovascular disease - Argenta Discovery/Teijin
Latest Information Update: 10 Nov 2006
At a glance
- Originator Argenta Discovery; Teijin Pharma
- Developer Argenta Discovery
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 10 Nov 2006 No development reported - Preclinical for Cardiovascular disorders in United Kingdom (unspecified route)
- 16 Jun 2003 Preclinical trials in Cardiovascular disorders in United Kingdom (unspecified route)